Tonix Pharmaceuticals Triples TONMYA Sales as Pipeline Advances — Tonix Pharmaceuticals Holding Corp.

Event summary

TONMYA net sales surged to $11 million, a 197% quarter-over-quarter increase.
Payer coverage for TONMYA expanded to approximately 136 million covered lives (43% of total U.S. lives).
First patient enrolled in Phase 2 HORIZON study of TNX-102 SL for major depressive disorder (MDD).
Phase 2 adaptive field study of TNX-4800 for Lyme disease prevention on track to start in Q1 2027.
$176.2 million in cash and cash equivalents as of June 30, 2026.

The big picture

Tonix Pharmaceuticals is rapidly scaling its commercial presence with TONMYA, while advancing a diverse pipeline targeting major depressive disorder and Lyme disease prevention. The company's strategic focus on expanding payer coverage and initiating key clinical trials positions it to capitalize on high-unmet medical needs in the CNS and infectious disease spaces.

What we're watching

Commercial Execution: Whether Tonix can sustain TONMYA's rapid sales growth with its expanded sales force and payer coverage.
Pipeline Progress: The pace at which TNX-102 SL and TNX-4800 advance through clinical trials and regulatory hurdles.
Financial Sustainability: How long Tonix's current cash position will last given its increasing operating expenses.